MedTrace Logo

64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)

NCT03951337 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-03-12

No results posted yet for this study

Summary

This phase II trial is assessing how 64Cu-ATSM (64Cu-copper(II) diacetylbis(N4-methylthiosemicarbazone)) PET/CT scan could predict neo adjuvant treatment response in rectum cancer locally advanced

Conditions

Interventions

DRUG

64Cu-ATSM

64 Cu-ATSM PET/CT scan

Sponsors & Collaborators

  • Fondation ARC

    collaborator OTHER

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • Mathilde COLOMBIE, MD · Institut de Cancerologie de l'Ouest

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-26
Primary Completion
2024-07-31
Completion
2026-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03951337 on ClinicalTrials.gov